Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Triamcinolone Acetonide

FDA-approved product (ointment, topical), marketed as Allernaze, Aristocort, Aristocort A and 24 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Triamcinolone Acetonide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Allergic rhinitis
  • Anemia
  • Asthma
  • Bursitis
  • Dermatitis
  • Epicondylitis
  • Frozen shoulder
  • Fungal infectious disease
  • Gout
  • Injury
  • Lateral epicondylitis
  • Multiple sclerosis
  • Nasal congestion
  • Osteoarthritis
  • Pain
  • Pulmonary tuberculosis
  • and 5 more

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

FDA pharmacologic class
Corticosteroid FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA52.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli35.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae24.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis30.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Triamcinolone Acetonide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Triamcinolone Acetonide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Phase I/II Trial of Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naive Infants

    NCT00322049 · start 2004-02

    Registered record
    Registry ID
    NCT00322049
    Conditions
    Dengue
    Interventions
    Tetravalent live attenuated dengue vaccine; Varicella vaccine and Haemophilus influenzae Type b Conjugate vaccine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2004-02
    Completion
    2009-06
    Enrolment
    51

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDengue
    InterventionTetravalent live attenuated dengue vaccine; Varicella vaccine and Haemophilus influenzae Type b Conjugate vaccine
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Use of Probiotics to Prevent Cholangitis in Children With Biliary Atresia After the Kasai Portoenterostomy

    NCT00166868 · start 2003-12

    Registered record
    Registry ID
    NCT00166868
    Conditions
    Biliary Atresia
    Interventions
    Lactobacillus casei rhamnosus (Lcr35); Neomycin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2003-12
    Completion
    2012-07
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBiliary Atresia
    InterventionLactobacillus casei rhamnosus (Lcr35); Neomycin
    PhaseNot applicable
    Registry statusCompleted

  • LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma

    NCT00062868 · start 2003-09

    Registered record
    Registry ID
    NCT00062868
    Conditions
    Hodgkin Disease; Non Hodgkin Lymphoma; Lymphoepithelioma; Leiomyosarcoma
    Interventions
    LMP1/2 CTLs (ALCI - Group A); LMP1/2 CTLs (ALCI - Group B); LMP1/2 CTLs (ALCI - Group C); LMP2 CTLs (ALSCER - Group A); LMP2 CTLs (ALSCER - Group B); LMP2 CTLs (ALSCER - Group C); LMP1/2 CTLs (ALCI - Expansion - Group A); LMP1/2 CTLs (ALCI - Expansion Group B); LMP1/2 CTLs (ALCI - Expansion Group C)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2003-09
    Completion
    2020-04
    Enrolment
    74

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHodgkin Disease; Non Hodgkin Lymphoma; Lymphoepithelioma; Leiomyosarcoma
    InterventionLMP1/2 CTLs (ALCI - Group A); LMP1/2 CTLs (ALCI - Group B); LMP1/2 CTLs (ALCI - Group C); LMP2 CTLs (ALSCER - Group A) +5 more
    PhasePhase 1
    Registry statusCompleted

  • Safety Study of Candidate Malaria Vaccine FMP1/AS02A in Healthy Adults in Bandiagara, Mali

    NCT00308061 · start 2003-07

    Registered record
    Registry ID
    NCT00308061
    Conditions
    Malaria
    Interventions
    FMP1/AS02A; Imovax Rabies Vaccine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2003-07
    Completion
    2005-07
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria
    InterventionFMP1/AS02A; Imovax Rabies Vaccine
    PhasePhase 1
    Registry statusCompleted

  • Epstein Barr Virus (EBV) Specific Cytotoxic T-Cells, Relapsed Lymphoma, ANGEL

    NCT00058617 · start 1996-01

    Registered record
    Registry ID
    NCT00058617
    Conditions
    Epstein-Barr Virus-Related Hodgkin Lymphoma; Epstein-Barr Virus-Related Non-Hodgkin Lymphoma; EBV Positive Plasma Cell Neoplasm
    Interventions
    Injection of EBV Specific CTLs
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    1996-01
    Completion
    2014-07
    Enrolment
    13

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEpstein-Barr Virus-Related Hodgkin Lymphoma; Epstein-Barr Virus-Related Non-Hodgkin Lymphoma; EBV Positive Plasma Cell Neoplasm
    InterventionInjection of EBV Specific CTLs
    PhasePhase 1
    Registry statusCompleted